Skip to content
Varubi, Varuby(rolapitant)
Varubi, Varuby (rolapitant) is a small molecule pharmaceutical. Rolapitant was first approved as Varubi on 2015-09-01. It is used to treat nausea and vomiting in the USA. It has been approved in Europe to treat nausea, neoplasms, and vomiting. It is known to target substance-P receptor.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Varubi
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Rolapitant hydrochloride
Tradename
Company
Number
Date
Products
VARUBITerSera TherapeuticsN-206500 RX2015-09-01
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
varubiNew Drug Application2020-08-19
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
nauseaHP_0002018D009325R11.0
vomitingHP_0002013D014839R11.1
Agency Specific
FDA
EMA
No data
Patent Expiration
Patent
Expires
Flag
FDA Information
Rolapitant Hydrochloride, Varubi, Tersera
91016152032-07-14U-1741
83615002029-10-09DP
84708422029-01-18U-1741
70493202028-08-19DS, DPU-1741
75638012027-04-04DP
79819052027-04-04U-1741
81785502027-04-04DS, DP
84047022027-04-04U-1741
ATC Codes
A: Alimentary tract and metabolism drugs
— A04: Antiemetics and antinauseants
— A04A: Antiemetics and antinauseants
— A04AD: Other antiemetics in atc
— A04AD14: Rolapitant
HCPCS
Code
Description
J2797
Injection, rolapitant, 0.5 mg
J8670
Rolapitant, oral, 1 mg
Clinical
Clinical Trials
223 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Neuromuscular blockadeD019148—52172145
AnesthesiaD000758—1781127
General anesthesiaD000768—372719
Muscle relaxationD009126—235110
Postoperative painD010149G89.18——1337
LaparoscopyD010535———426
Muscle weaknessD018908HP_0001324——1214
Delayed emergence from anesthesiaD055191———314
Morbid obesityD009767EFO_0001074———224
Rapid sequence induction and intubationD000079603——2114
Show 50 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Heart arrestD006323EFO_0009492I46—11—13
Pancreatic neoplasmsD010190EFO_0003860C25——1——1
Lung neoplasmsD008175C34.90—11——1
Nerve blockD009407——1——1
Back painD001416HP_0003418M54——1——1
Local anesthesiaD000772——1——1
Spinal fusionD013123——1——1
Organophosphate poisoningD062025—11——1
Muscle fatigueD018763——1——1
HypothermiaD007035HP_0002045T68——1——1
Show 4 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Renal insufficiencyD051437HP_0000083N19—1———1
Out-of-hospital cardiac arrestD058687—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
DeliriumD003693R41.01———23
High-frequency jet ventilationD0066111————1
Spinal fracturesD016103EFO_0003902S121————1
Spinal stenosisD013130EFO_0007490M48.01————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
PharyngitisD010612R07.0————33
Critical illnessD016638————22
Patient satisfactionD017060————22
Neuromuscular monitoringD061886————22
StrabismusD013285HP_0000486H50.2————11
MelanomaD008545————11
Colorectal neoplasmsD015179————11
FasciculationD005207R25.3————11
PneumothoraxD011030J93.11————11
BronchoscopyD001999————11
Show 20 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameROLAPITANT
INNrolapitant
Description
Rolapitant is an azaspiro compound that is 1,7-diazaspiro[4.5]decan-2-one carrying additional phenyl and 1-{[3,5-bis(trifluoromethyl)phenyl]ethoxy}methyl substituents at position 8. Used (in the form of the hydrochloride hydrate) for the prevention of delayed nausea and vomiting associated with initial and repeat courses of emetogenic cancer chemotherapy. It has a role as an antiemetic and a neurokinin-1 receptor antagonist. It is an ether, an azaspiro compound, a member of pyrrolidin-2-ones, a member of piperidines and an organofluorine compound. It is a conjugate base of a rolapitant(1+).
Classification
Small molecule
Drug classtachykinin (neurokinin) receptor antagonists: NK1 receptor antagonists
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@@H](OC[C@@]1(c2ccccc2)CC[C@]2(CCC(=O)N2)CN1)c1cc(C(F)(F)F)cc(C(F)(F)F)c1
Identifiers
PDB—
CAS-ID552292-08-7
RxCUI1665496
ChEMBL IDCHEMBL3707331
ChEBI ID—
PubChem CID10311306
DrugBankDB09291
UNII IDNLE429IZUC (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
TACR1
TACR1
Organism
Homo sapiens
Gene name
TACR1
Gene synonyms
NK1R, TAC1R
NCBI Gene ID
Protein name
substance-P receptor
Protein synonyms
neurokinin receptor 1, NK-1 receptor, NK-1R, Tachykinin receptor 1, tachykinin receptor 1 (substance P receptor; neurokinin-1 receptor)
Uniprot ID
Mouse ortholog
Tacr1 (21336)
substance-P receptor (Q8BYR7)
Variants
Clinical Variant
No data
Financial
Varubi - Tesaro
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 231 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
5,365 adverse events reported
View more details